TRINETRA › Sectors › Healthcare
Alembic Pharmaceuticals Limited (APLLTD) — share price, P/E and fundamentals
Alembic Pharmaceuticals Limited (NSE: APLLTD) closed at ₹798.65 on 30 Oct 2026, -14.9% over one year, against a 52-week range of ₹635.80 – ₹998.00.
In the quarter ended 30 Jun 2026 (consolidated, filed 4 Aug 2026) it reported revenue of ₹2,150 cr and net profit of ₹173 cr, a 8.1% net margin; revenue grew 25.7% and profit grew 16.2% year on year.
On four consecutive filed quarters its trailing P/E is 22.8; since 12 May 2025 its own P/E has ranged from 20.2 to 35.0 (median 25.7), and today's reading is higher than 17% of those 364 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 12.2%, ROCE 16.2%, debt-to-equity 0.24, Piotroski F-score 7 of 9.
Against 66 Healthcare peers on NSE: Net margin higher than 19% of 64 sector peers; PBT margin higher than 16% of 64 sector peers; ROE higher than 42% of 64 sector peers.
Key figures
| Last close | ₹798.65 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -6.0% / +6.3% / -14.9% |
| 52-week low – high | ₹635.80 – ₹998.00 |
| Market capitalisation | ₹15,697 cr |
| Trailing P/E | 22.8 |
| Price / book | 2.77 |
| EV / EBITDA | 14.5 |
| Earnings yield | 4.4% |
| TTM EPS | ₹35.08 |
| TTM net profit | ₹690 cr |
| Quarter revenue | ₹2,150 cr |
| Quarter net profit | ₹173 cr |
| Net margin | 8.1% |
| Revenue growth (YoY) | +25.7% |
| Profit growth (YoY) | +16.2% |
| Return on equity | 12.2% |
| ROCE | 16.2% |
| Debt / equity | 0.24 |
| Current ratio | 1.75 |
| Free cash flow | ₹348 cr |
| Piotroski F-score | 7 / 9 |
| Average daily turnover (50 days) | ₹11.1 cr |
Against Healthcare peers
| Metric | APLLTD | Peer median | Percentile |
|---|---|---|---|
| Net margin | 8.05 | 12.89 | 19 |
| PBT margin | 10.30 | 17.68 | 16 |
| ROE | 12.20 | 13.87 | 42 |
| ROCE | 16.15 | 17.26 | 47 |
| Debt / equity | 0.24 | 0.11 | 64 |
| Cash conversion | 1.17 | 1.25 | 45 |
| Trailing P/E | 22.76 | 43.26 | 8 |
| P/B | 2.77 | 6.02 | 8 |
Questions
What is the P/E ratio of Alembic Pharmaceuticals Limited?
Alembic Pharmaceuticals Limited's trailing P/E is 22.8, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 12 May 2025 its P/E has ranged 20.2–35.0.
What were Alembic Pharmaceuticals Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Alembic Pharmaceuticals Limited reported revenue of ₹2,150 cr and net profit of ₹173 cr (consolidated), filed with the exchange on 4 Aug 2026.
What is Alembic Pharmaceuticals Limited's ROE?
Return on equity is 12.2% based on the balance sheet dated 31 Mar 2026.
Does Alembic Pharmaceuticals Limited have debt?
Debt-to-equity is 0.24 on the balance sheet dated 31 Mar 2026.
What is APLLTD's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, APLLTD traded between ₹635.80 and ₹998.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.